Silvia Bianchi1, Sara Boveri2, Sarah Igidbashian2, Antonella Amendola1,3,4, Ailyn Mariela Vidal Urbinati2, Elena Rosanna Frati1, Fabio Bottari5, Daniela Colzani1, Fabio Landoni2, Elisabetta Tanzi6,7,8, Mario Sideri2, Maria Teresa Sandri5. 1. Department of Biomedical Sciences for Health, University of Milan, Via Carlo Pascal, 36, 20133, Milan, Italy. 2. Preventive Gynecology Unit, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy. 3. Coordinated Research Center "EpiSoMI", University of Milan, Via Carlo Pascal, 36, 20133, Milan, Italy. 4. CIRI-IV, Department of Health Sciences, University of Genoa, Via Antonio Pastore, 1, 16132, Genoa, Italy. 5. Division of Laboratory Medicine, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy. 6. Department of Biomedical Sciences for Health, University of Milan, Via Carlo Pascal, 36, 20133, Milan, Italy. elisabetta.tanzi@unimi.it. 7. Coordinated Research Center "EpiSoMI", University of Milan, Via Carlo Pascal, 36, 20133, Milan, Italy. elisabetta.tanzi@unimi.it. 8. CIRI-IV, Department of Health Sciences, University of Genoa, Via Antonio Pastore, 1, 16132, Genoa, Italy. elisabetta.tanzi@unimi.it.
Abstract
PURPOSE: This study investigated the prevalence of Chlamydia trachomatis infection, co-infection with Human Papillomavirus (HPV) and associated risk factors in a cohort of sexually active young women enrolled in an ongoing trial on HPV vaccination at the European Institute of Oncology (IEO, Milan, Italy). METHODS: Cervical samples were collected from 591 girls (median age 18.8 years) at the beginning of their sexual activity. At the time of sample collection, 354 women had not yet been vaccinated, and 237 women had been vaccinated for at least 12 months. All samples were analyzed through a molecular assay for the detection of C. trachomatis infection. Demographic, behavioral risk factors and high-risk HPV (HR-HPV) status were investigated. RESULTS: The prevalence of C. trachomatis infection was 4.9 % and HPV/C. trachomatis co-infection rate was 1.5 %. The exact analysis has not underlined statistical significance for the variables considered, except for the infection with HR-HPV (p < 0.001). The prevalence of C. trachomatis infection among women who had not been immunized and those already vaccinated was similar (5.6 vs 3.8 %). However, the rate of HPV/C. trachomatis co-infection was twice as high in unvaccinated women (2 %) compared to vaccinated women (0.8 %). CONCLUSIONS: Over 16 % of young women had at least one of the two STIs investigated. The risk of C. trachomatis infection was higher in HR-HPV infected compared to HR-HPV uninfected young women. The rate of co-infection was halved in HPV-vaccinated compared to unvaccinated women. This study underlines that HPV vaccination can confer benefits also in terms of co-infections prevention, leading to a decreased risk of developing cervical malignancies.
PURPOSE: This study investigated the prevalence of Chlamydia trachomatis infection, co-infection with Human Papillomavirus (HPV) and associated risk factors in a cohort of sexually active young women enrolled in an ongoing trial on HPV vaccination at the European Institute of Oncology (IEO, Milan, Italy). METHODS: Cervical samples were collected from 591 girls (median age 18.8 years) at the beginning of their sexual activity. At the time of sample collection, 354 women had not yet been vaccinated, and 237 women had been vaccinated for at least 12 months. All samples were analyzed through a molecular assay for the detection of C. trachomatis infection. Demographic, behavioral risk factors and high-risk HPV (HR-HPV) status were investigated. RESULTS: The prevalence of C. trachomatis infection was 4.9 % and HPV/C. trachomatis co-infection rate was 1.5 %. The exact analysis has not underlined statistical significance for the variables considered, except for the infection with HR-HPV (p < 0.001). The prevalence of C. trachomatis infection among women who had not been immunized and those already vaccinated was similar (5.6 vs 3.8 %). However, the rate of HPV/C. trachomatis co-infection was twice as high in unvaccinated women (2 %) compared to vaccinated women (0.8 %). CONCLUSIONS: Over 16 % of young women had at least one of the two STIs investigated. The risk of C. trachomatis infection was higher in HR-HPV infected compared to HR-HPV uninfected young women. The rate of co-infection was halved in HPV-vaccinated compared to unvaccinated women. This study underlines that HPV vaccination can confer benefits also in terms of co-infections prevention, leading to a decreased risk of developing cervical malignancies.
Authors: Hanna Bergman; Brian S Buckley; Gemma Villanueva; Jennifer Petkovic; Chantelle Garritty; Vittoria Lutje; Alina Ximena Riveros-Balta; Nicola Low; Nicholas Henschke Journal: Cochrane Database Syst Rev Date: 2019-11-22
Authors: Marianna Martinelli; Rosario Musumeci; Alberto Rizzo; Narcisa Muresu; Andrea Piana; Giovanni Sotgiu; Fabio Landoni; Clementina Cocuzza Journal: Int J Environ Res Public Health Date: 2019-09-11 Impact factor: 3.390
Authors: Marianna Martinelli; Rosario Musumeci; Illari Sechi; Giovanni Sotgiu; Andrea Piana; Federica Perdoni; Federica Sina; Robert Fruscio; Fabio Landoni; Clementina E Cocuzza Journal: Int J Environ Res Public Health Date: 2019-12-09 Impact factor: 3.390
Authors: Jane Rowley; Stephen Vander Hoorn; Eline Korenromp; Nicola Low; Magnus Unemo; Laith J Abu-Raddad; R Matthew Chico; Alex Smolak; Lori Newman; Sami Gottlieb; Soe Soe Thwin; Nathalie Broutet; Melanie M Taylor Journal: Bull World Health Organ Date: 2019-06-06 Impact factor: 9.408